AGT and early-onset autosomal dominant Alzheimer disease: These observations stimulated an interest in developing improved IRAP inhibitors, more potent than the short-lived endogenous Ang IV, as a new class of cognitive enhancers and as potential therapeutics for treating a variety of cognitive disorders such as Alzheimer’s disease [22,23,24].